🔎 Trials Near Me

Home › Hidradenitis Suppurativa › New York › New York City

Hidradenitis Suppurativa clinical trials in New York City, NY

5 studies for Hidradenitis Suppurativa are looking for participants at sites in and around New York City (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

RecruitingPhase 3
  • Cameron Dermatology, New York
  • Icahn School Of Med At Mount Sinai, New York
Ages 18 to 100 · All sexes · Updated Sep 28, 2026 · NCT07665437

Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa

RecruitingPhase 1
  • Clinical Site 5, New York
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07828860

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

RecruitingPhase 1
  • Dr Bobby Buka, Md Greenwich Village, New York
  • Equity Medical, Llc, New York
Ages 12 to 75 · All sexes · Updated Sep 15, 2026 · NCT07049575

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

RecruitingPhase 3
  • Investigative Site US034, New York
  • Investigative Site US081, New York
  • Investigative Site US065, New York
  • and 1 more
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06855498

A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

RecruitingPhase 2
  • Mount Sinai Doctors, New York
Ages 18 and older · All sexes · Updated Mar 6, 2026 · NCT07244263

About Hidradenitis Suppurativa

Hidradenitis suppurativa (HS), or acne inversa, is a chronic skin disease. It causes painful bumps in your armpits and groin. Learn about treatment.

More about Hidradenitis Suppurativa on MedlinePlus

Hidradenitis Suppurativa trials in other cities

Other studies in New York City

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.